NewcelX Ltd. (NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (ELDN), a clinical-stage immunology company with a focus on transplant medicine. It is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart or AT-1501, with the goal of supporting durable, immune-protected islet replacement and advancing a potential functional cure for Type 1 Diabetes.
The company said the collaboration is anticipated to accelerate timelines, establish a well-defined regulatory pathway, and enhance development visibility, supporting NewcelX's strategy to advance its clinical programs efficiently toward pivotal milestones.
NewcelX shares are currently trading at $2.9450, up 6.32%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.